| Market Cap | 1.74B | P/E | - | EPS this Y | 137.00% | Ern Qtrly Grth | - |
| Income | -155.2M | Forward P/E | 304.14 | EPS next Y | 170.00% | 50D Avg Chg | -6.00% |
| Sales | 802.2M | PEG | -32.96 | EPS past 5Y | -37.87% | 200D Avg Chg | 4.00% |
| Dividend | N/A | Price/Book | 2.08 | EPS next 5Y | -8.20% | 52W High Chg | -24.00% |
| Recommedations | 2.70 | Quick Ratio | 1.45 | Shares Outstanding | 90.82M | 52W Low Chg | 53.00% |
| Insider Own | 2.07% | ROA | -5.68% | Shares Float | 83.24M | Beta | 1.93 |
| Inst Own | 103.87% | ROE | -21.03% | Shares Shorted/Prior | 3.94M/3.88M | Price | 21.29 |
| Gross Margin | 69.07% | Profit Margin | -19.35% | Avg. Volume | 519,954 | Target Price | 29.93 |
| Oper. Margin | -11.77% | Earnings Date | Nov 4 | Volume | 294,898 | Change | -2.20% |
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
| Morgan Stanley | Equal-Weight | Sep 19, 24 |
| Wells Fargo | Overweight | Aug 27, 24 |
| Scotiabank | Sector Outperform | Aug 13, 24 |
| Piper Sandler | Neutral | Aug 13, 24 |
| TD Cowen | Hold | Aug 7, 24 |
| JP Morgan | Underweight | Aug 7, 24 |
| Scotiabank | Sector Outperform | Jun 27, 24 |
| Piper Sandler | Neutral | May 13, 24 |
| Leerink Partners | Outperform | May 8, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Riggsbee Richard Bryan | Chief Financial Offi.. Chief Financial Officer | Nov 01 | Sell | 15.6874 | 30,000 | 470,622 | 321,812 | 11/03/23 |
| SPIEGELMAN DANIEL K | Director Director | Jun 01 | Sell | 23.01 | 8,638 | 198,760 | 40,493 | 06/02/23 |
| Lambert Nicole | Chief Operating Offi.. Chief Operating Officer | Mar 27 | Sell | 23.48 | 6,433 | 151,047 | 240,506 | 03/28/23 |
| Lambert Nicole | Chief Operating Offi.. Chief Operating Officer | Mar 02 | Sell | 22.7414 | 13,184 | 299,823 | 215,220 | 03/03/23 |
| Riggsbee Richard Bryan | Chief Financial Offi.. Chief Financial Officer | Jan 18 | Sell | 20.01 | 600 | 12,006 | 373,507 | 01/19/23 |
| SPIEGELMAN DANIEL K | Director Director | Jun 06 | Sell | 19.2517 | 6,424 | 123,673 | 33,980 | 06/06/22 |
| Hart Jayne B. | Chief People Officer Chief People Officer | Feb 28 | Option | 23.98 | 10,500 | 251,790 | 169,378 | 03/01/22 |
| Hart Jayne B. | Chief People Officer Chief People Officer | Feb 28 | Sell | 25 | 10,500 | 262,500 | 165,878 | 03/01/22 |
| LANCHBURY JERRY S | Chief Scientific Off.. Chief Scientific Officer | Aug 25 | Option | 27.07 | 80,000 | 2,165,600 | 262,550 | 08/25/21 |
| LANCHBURY JERRY S | Chief Scientific Off.. Chief Scientific Officer | Aug 25 | Sell | 35.4 | 80,000 | 2,832,000 | 232,550 | 08/25/21 |
| Phanstiel S. Louise | Director Director | Aug 06 | Option | 23.34 | 60,000 | 1,400,400 | 91,646 | 08/06/21 |
| LANCHBURY JERRY S | Chief Scientific Off.. Chief Scientific Officer | Jul 08 | Option | 26.49 | 32,308 | 855,839 | 234,434 | 07/08/21 |
| LANCHBURY JERRY S | Chief Scientific Off.. Chief Scientific Officer | Jun 28 | Option | 19.47 | 50,000 | 973,500 | 294,562 | 06/28/21 |
| LANCHBURY JERRY S | Chief Scientific Off.. Chief Scientific Officer | Jun 28 | Sell | 32.02 | 83,372 | 2,669,571 | 232,550 | 06/28/21 |
| LANCHBURY JERRY S | Chief Scientific Off.. Chief Scientific Officer | May 05 | Option | 19.47 | 19,360 | 376,939 | 285,282 | 05/05/21 |
| LANCHBURY JERRY S | Chief Scientific Off.. Chief Scientific Officer | May 05 | Sell | 31.97 | 19,360 | 618,939 | 265,922 | 05/05/21 |
| Lambert Nicole | See Remarks See Remarks | Apr 20 | Sell | 27.01 | 6,649 | 179,589 | 129,119 | 04/20/21 |
| Hart Jayne B. | Chief People Officer Chief People Officer | Mar 30 | Option | 23.08 | 58,000 | 1,338,640 | 88,162 | 03/30/21 |
| Hart Jayne B. | Chief People Officer Chief People Officer | Mar 30 | Sell | 30 | 58,000 | 1,740,000 | 80,128 | 03/30/21 |